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Background: Serological tests can distinguish recent (in the prior
12 months) from long-term HIV infection. Integrating recency
testing into routine HIV testing services (HTS) can provide
important information on transmission clusters and prioritize clients
for partner testing. This study assessed the feasibility and use of
integrating HIV recency into routine testing.
Methods: We conducted a multi-method study at 14 facilities in
Kenya, and key informant interviews with health care providers. We
abstracted clinical record data, collected specimens, tested specimens
for recent infection, returned results to participants, and conducted
a follow-up survey for those recently infected.
Results: From March to October 2018, we enrolled 532 clients who
were diagnosed HIV-positive for the first time. Of these, 46 (8.6%)
were recently infected. Women aged 15–24 years had 2.9 (95%
confidence interval: 1.46 to 5.78) times higher adjusted odds of
recent infection compared with 15–24-year-old men and those tested
within the past 12 months having 2.55 (95% confidence interval:
0.38 to 4.70) times higher adjusted odds compared with those tested
$12 months previously. Fourteen of 17 providers interviewed found
the integration of recency testing into routine HTS services accept-
able and feasible. Among clients who completed the follow-up
interview, most (92%) felt that the recency results were useful.
Conclusions: Integrating recent infection testing into routine HTS
services in Kenya is feasible and largely acceptable to clients and
providers. More studies should be done on possible physical and
social harms related to returning results, and the best uses of the
recent infection data at an individual and population level.
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INTRODUCTION
UNAIDS has set global goals for 95% of all people
living with HIV (PLHIV) to be diagnosed, 95% of these to be
initiated and retained on antiretroviral therapy (ART), and
95% of these to be virally suppressed (95-95-95) by 2030 (see
Supplemental Digital Content 1, http://links.lww.com/QAI/
B439).1 Achieving 95% diagnosis will require new ap-
proaches to maximize case finding. One such approach is
the latent antigen avidity assay for recent HIV infection.2–6
When used in combination with viral load (VL) testing [ie,
the recent infection testing algorithm (RITA)], it can identify
persons whose infection occurred within the last 12
months.7–12 These assays can be integrated into HIV
surveillance systems and testing programs to identify groups
with high incidence, characterize current risk factors for
infection, and target hot spots of transmission among the
hardest-to-reach populations, and through contact tracing
identify PLHIV who have not been diagnosed, PLHIV who
have fallen out of care, and uninfected individuals at high risk
of infection who may benefit from pre-exposure prophylaxis.5
Integrating RITA, which pairs recency and VL
assays, and where possible antiretroviral (ARV) metabolite
testing, to minimize the false recency rate11,12 into HIV
testing and counseling (HTC) services, has been proposed
as a means to identify geographic areas and populations
with ongoing transmission to better target prevention
programs and index testing efforts.14 However, before
scale-up, national HIV programs need to evaluate the risks
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and benefits of conducting recency testing and whether
there is an ethical obligation to return results to clients.
More data are needed on potential harms of knowing recent
infection status and whether there are increased rates of
intimate partner violence or other social harms related to
disclosing recent HIV status compared with disclosing HIV
infection in general. In addition, facilities will need to
determine how to use recency test results to support partner
notification. The use should be evaluated in light of the
added costs and time related to recent infection testing in
routine HTC.
We assessed the acceptability and feasibility of integrating
recency testing into routine HTC services and identified and
characterized recent HIV infections among newly-diagnosed
clients attending HTC services Eastern Deanery AIDS Relief
Programme (EDARP) facilities in Nairobi, Kenya.15
METHODS
Clients presenting for routine HTC at all 14 EDARP
facilities were screened for eligibility. We invited clients who
were $15 years old and had received an HIV-positive result for
the first time between March and October 2018 to participate.
Informed consent was administered in English or Swahili. Those
who declined consent proceeded with treatment per national
guidelines. Health care providers returned RITA results and
provided post-test counselling to participants and at a subsequent
visit, administered a follow-up survey on partner notification and
testing, intimate partner violence, and initiation of ART to
participants with recent infections. All persons testing HIV-
positive were encouraged to refer partners for HIV testing
through index testing, per standard of care.
Once consent was obtained, we collected 6.0 mL of
venous blood in an EDTA tube and pipetted samples onto 2
Whatman 903 Snap-Apart Cards with 5 dried blood spots of 70
mL each, for a total of 10 filled spots per participant. We
abstracted demographic and clinical variables from each
participant’s electronic health record. Testing for recent
infection was performed using RITA that combined the
limiting antigen avidity enzyme immunoassay (LAg Avidity
EIA) (Maxim Biomedical, Rockville, MD) VL testing, and
ARV metabolite testing to confirm classification of recent
infections. The LAg testing protocol requires the assay to be
performed twice. Specimens with an ODn value of #1.5 were
confirmed by further testing of the samples. The ODn is
calculated by dividing the optical density (OD) for each
specimen by the median OD of the calibrator. We measured
HIV-1 RNA VL using the Abbott m2000, Roche Cobas
Ampliprep/Cobas TaqMan (Roche Diagnostics USA, Indian-
apolis, IN). Specimens in which VL was #1000 copies/mL
were classified as “long-term” infections, irrespective of the
assay result. Specimens in which VL was .1000 copies/mL
and ODn #1.5 were classified as “recent” infections, ie,
infections acquired in the prior 12 months. Because prior ARV
exposure affects the accuracy of the LAg assay, we also tested
samples classified as recent infections for the presence of
efavirenz, nevirapine, atazanavir, and lopinavir metabolites in
the blood. Qualitative detection of ARV drugs was performed
on LAg-positive samples using high-performance liquid chro-
matography coupled with tandem mass spectrometry. Samples
above the lower limit of detection (,0.02 mg/mL) for any of
the ARV drugs tested were classified as ARV-positive. VL
testing was conducted at the EDARP laboratory in Nairobi,
LAg testing was conducted at the National HIV Reference
Laboratory in Nairobi, and ARV metabolite testing was
conducted at the University of Cape Town in South Africa.
We performed multivariable logistic regressions to exam-
ine associations between predictor variables and recent infection
using STATA 14.2 (Stata Corporation, College Station, TX). In
the final model, we retained variables that had a P-value less
than 0.05. We disaggregated the final model by gender.
Qualitative Analysis
We also conducted key informant interviews with
purposively selected health care providers from EDARP
facilities in November 2018 using a semi-structured interview
guide. We reviewed audio recordings of interviews 3 times. A
summary was developed for each interview, which included
illustrative quotes we transcribed verbatim. We used a coding
scheme, based on the interview guide, to code all interviews
and classical content analysis to analyze the data.
Participants including key informants provided consent
before participating in the study. The study was approved by
ethical review boards at the University of California, San
Francisco, the Kenyatta National Hospital, the London
School of Hygiene and Tropical Medicine and EDARP.
RESULTS
A total of 883 persons tested positive for HIV at the 14
study sites. Of those, 255 had previously tested positive and
were, therefore, ineligible. Ninety-six did not consent to
participate; 532 were eligible, consented to participate, and
enrolled in the study (Fig. 1).
Four hundred seventy participants (88%) had an ODn
value of .1.5, and were accordingly classified as long-term
infections. Sixty-two participants (12%) had an ODn value of
#1.5 and required VL testing to confirm the recency classifi-
cation; of those, 12 (22%) were classified as long-term after VL
testing; 2 participants had insufficient volume for VL testing and
were excluded. Of the 62 participants, 48 (77%) were classified
as recent per the RITA and sent for ARV metabolite testing; 2
(4%) had ARV metabolites present and were reclassified as
long-term infections. Thus, 46 (9%) of all participants tested and
71% of those initially positive on LAg avidity assay were
classified as recent after all confirmatory tests were completed.
A higher proportion of recent infection was found among
women [adjusted odds ratio (aOR) = 4.20, P , 0.001], those
under 25-years-old (aOR = 3.55, P, 0.001), and those who had
been tested in the prior 12 months (aOR = 2.55, P , 0.001).
Testing for interactions revealed an interaction between age at
diagnosis and gender. As noted in the Table 1, 15-to-29-year-old
women had 2.9 times higher adjusted odds of recent infection
than men in the same age group.
Of the 532 participants, 402 (76%) received their results;
29 (61%) of the 46 recently infected participants received their
results. Of those, 13 (46%) completed the follow-up
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questionnaire. Overall, clients who received a recent HIV test
result found recency testing to be acceptable and clinically
useful. A large majority (92%) of participants reported that the
recency result encouraged them to seek treatment sooner than
they would have otherwise and in particular liked getting their
VL results to monitor how they were doing. Ten participants
(76.9%) also reported telling at least one sexual partner to be
tested for HIV; of these, 6 presented at the site for HIV testing.
Four participants (31%) reported experiencing violence or
stigma after getting their results, and a little over half (54%)
reported that the result had a negative impact on their relation-
ships. There was, however, no way to disentangle negative
experiences related to HIV status and recency status disclosure.
In most of the cases, the harm came before the recency results
were returned, suggesting that it was related to HIV status
disclosure and not recency status. Of the 19 participants who
tested positive for recent infection and did not receive results, 7
were lost to follow-up, 5 travelled out of Nairobi and did not
return, and 7 said they did not want to receive results.
Partner Notification
One hundred forty-four (27%) of newly diagnosed
participants (both with recent and long-term infection)
brought sexual partners to be tested. Two participants
brought 2 partners. Of the 48 recently infected clients, 13
referred 13 partners (0.27 partners/index patient), and of the
482 clients with long-term infection, 131 referred 133
partners (0.27 partners/index patient). Of the 146 index
partners referred, 31 (21%) were newly diagnosed with HIV
infection; 30 (21%) had been previously diagnosed. Five
(39%) of 13 partners of clients with recent infection were
found to be HIV infected, 80% of them (4 of 5) were
unaware of their status. On the other hand 56 (44%) of 133
partners of clients with long-term infection were found to be
HIV infected and 48.2% (27 of 56) were unaware of their
status (P = NS). Of the 31 partners newly diagnosed with
HIV infection, twenty-one consented to recency testing; 5
(23.8%) had recent infection. HIV seroprevalence among
partners was 25 times that of routine testing of individuals
through HTS (42% compared to 1.7%).
Acceptability and Feasibility of Integrated
Recent Infection Testing into HTC
Seventeen EDARP health care providers were inter-
viewed. Fourteen indicated that recent infection testing was
acceptable and feasible.1 Identified benefits included
improved ART adherence, more effective treatment monitor-
ing, increased partner notification, and strengthened
client–provider rapport. Providers did not report any
adverse events related to the study, although they acknowl-
edged the potential for testing results to instigate conflict or
violence. One provider recounted her experience with
FIGURE 1. Study client flow chart.
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a recently infected study participant: “The way he was ex-
pressing himself it is like he went to confront the lady”.
Another reported that a participant refused recency testing
because he was afraid he “might kill the person who infected
[him].” When asked about participant perspectives regarding
recent infection testing, health care providers gave mixed
responses. Perception of negative participant perspective
included disinterest, risk of retraumatization, and fear of
interpersonal conflict.
DISCUSSION
We found that 8.6% of persons newly diagnosed with
HIV infection at EDARP sites had been recently infected.
Young women had the highest proportion of new infections.
This may be related to the gender differences in care-
seeking.16,17 Work-related mobility, clinic hours, and gender
norms often discourage men from seeking health care
early.18,19 Differential health-seeking behavior affects the
use of recent infection data to estimate incidence and in
tracking the epidemic.
Our study corroborated that partner notification services
are very effective in increasing yield in routine HIV testing;
however, our sample was too small to say whether index
clients with recent infection are more likely to refer partners
with recent infection. What is apparent is that recent
infections identified more persons who were unaware of their
serostatus.
Interviews with health care providers revealed unex-
pected clinical benefits associated with recent infection
testing. Clients seemed to view recent infection status and
VL measurement as indicators of disease progression; those
with confirmed recent infections or low VL were hopeful for
favorable health outcomes, which encouraged adherence. A
full evaluation needs to be done to understand whether
recency infection testing increases the risk of psychosocial
harm or intimate partner violence beyond the risks associated
with HIV status disclosure.
Our study had limitations. Our sample was small and,
moreover, unlikely representative of all HIV-infected people
living in the EDARP catchment area. We are therefore unable to
make broad generalizations or to calculate incidence accurately.
CONCLUSIONS
We found that integrating recent infection testing into
routine HTC services in Kenya is feasible and acceptable.
More data are needed to understand issues related to return of
results and how best to use individual and population data on
recent infection.
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TABLE 1. Predictors of Recent Infection and Predictors of Recent Infection Disaggregated by Gender*
Recent (N = 46) Female
N Percent OR 95% CI aOR 95% CI N aOR 95% CI
Sex
Male 7 3.2% — —
Female 39 12.3% 4.20 1.80 to 9.60† 2.82 1.19 to 6.69†
Age range
15–24 21 18.4% 3.55 1.90 to 6.60† 2.57 1.33 to 4.95† 21 2.90 1.46 to 5.78†
25+ 25 19.1% — — 18 — —
Reside in catchment area
Yes 41 9.0% 1.45 0.55 to 3.80
No 5 6.4%
Highest level of education
Primary or none 18 6.5% 0.55 0.30 to 1.0
Secondary and above 28 11.1% — —
Tested for HIV in last 12 months
Yes, tested for HIV within last 12 months 25 14.0% 2.55 1.38 to 4.70† 2.13 1.13 to 4.00† 16 2.35 1.18 to 5.78†
No, did not test for HIV within last 12 months 21 6.0% — — 23 — —
Pregnancy status (n = 316)
Pregnant 10 17.5% 1.69 0.77 to 3.70
Not pregnant 29 11.2% — —
*A strong interaction between gender and age was observed (P-value) therefore we used a separate model disaggregated by gender. There were no males in the youngest catergory
therefore only females are shown in the table.
†Significant at the 0.05 level.
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